JP2920151B2 - Antiallergic agent - Google Patents
Antiallergic agentInfo
- Publication number
- JP2920151B2 JP2920151B2 JP2057392A JP5739290A JP2920151B2 JP 2920151 B2 JP2920151 B2 JP 2920151B2 JP 2057392 A JP2057392 A JP 2057392A JP 5739290 A JP5739290 A JP 5739290A JP 2920151 B2 JP2920151 B2 JP 2920151B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- antiallergic agent
- aqueous phase
- tea
- extract obtained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
【発明の詳細な説明】 （産業上の利用分野） 本発明は、抗アレルギー剤に関する。Description: TECHNICAL FIELD The present invention relates to an antiallergic agent.
（従来の技術） アレルギー反応は抗原抗体反応により組織に傷害を与
える現象で、その発症メカニズムによってＩ型（即時
型）からIV（遅延型）の４種に分類されている。このう
ちＩ型アレルギーは、抗原によりIgE感作肥満細胞が特
異的に刺激され、化学伝達物質が遊離され炎症をひきお
こすとされている。(Prior Art) Allergic reactions are phenomena that damage tissues by antigen-antibody reactions, and are classified into four types, from type I (immediate type) to IV (delay type), depending on the onset mechanism. Among these, type I allergy is said to specifically stimulate IgE-sensitized mast cells by antigens, release chemical messengers, and cause inflammation.
茶葉抽出物の抗アレルギー剤としての利用は、特開昭
59−1986884号で新規なるタンニンと称されるTeasinens
in A.Teasinensin B.または、次の一般式で表される物
質が示されている。The use of tea leaf extract as an antiallergic agent is disclosed in
Teasinens referred to as new tannins in 59-1986884
In A. Teasinensin B. or a substance represented by the following general formula is shown.
（本発明が解決しようとする課題） しかしながら、上記新規なるタンニンは非常に単離精
製が困難であり収率も低い。例えばTeasinensin Aは新
鮮茶葉からの収率が0.00040％、Teasinensin Bは0.0001
3％と記されている。 (Problems to be Solved by the Invention) However, the novel tannin is very difficult to isolate and purify, and the yield is low. For example, Teasinensin A has a yield of 0.00040% from fresh tea leaves, and Teasinensin B has a yield of 0.0001%.
It is marked as 3%.
本発明者は、茶葉中の物質には、強力な抗酸化力、血
中コレステロール抑制、血液降下、抗菌、抗ガン、消臭
などの機能、用途があるとの知見に基づき、この点から
実用化を可能にすべく研究したものであり、Ｉ型アレル
ギーに対する治療薬を開発する一つの方法である肥満細
胞からのヒスタミン遊離抑制活性を指標に、特に紅茶、
ウーロン茶抽出物の活性に注目した。その結果、本発明
者らは、紅茶抽出物の中でも特に、抽剤としてメチル−
イソ−ブチルケトン（MIBE）と１−ブタノール（BuOH）
を使用して分配抽出を行った時に得られる抽出残渣、こ
の残渣をカラムクロマト法で分離した際の親水性有機溶
媒溶出物、更にこの溶出物を膜分離したものが強い抑制
効果を示すこと、また、ウーロン茶についても同様に抽
出を行った結果、それぞれの抽出物残渣乃至抽出物がや
はり特に強い抑制効果を示すことを見い出した。The present inventor has found that substances in tea leaves have functions and uses such as strong antioxidant power, suppression of blood cholesterol, blood drop, antibacterial, anticancer, deodorant, etc. It has been studied to make it possible to convert histamine from mast cells, which is one method of developing a therapeutic agent for type I allergy.
Attention was paid to the activity of oolong tea extract. As a result, the present inventors found that, among black tea extracts, methyl-
Iso-butyl ketone (MIBE) and 1-butanol (BuOH)
Extraction residue obtained when performing partition extraction using, a hydrophilic organic solvent eluate when this residue is separated by column chromatography, furthermore, the one obtained by membrane separation of this eluate shows a strong inhibitory effect, In addition, as a result of similarly extracting oolong tea, it was found that each extract residue or extract also exhibited a particularly strong inhibitory effect.
そこで本発明は、以上の知見に基づいて抗アレルギー
剤を提供せんとするものである。Therefore, the present invention aims to provide an antiallergic agent based on the above findings.
（課題を解決するための手段） 上記課題を解決するために、本発明の抗アレルギー剤
は、紅茶又はウーロン茶を水乃至熱水で抽出して得られ
る抽出成分を水に溶解し、これにメチル−イソ−ブチル
ケトン（MIBK）を加えて分配抽出し、得られる水相抽出
成分に１−ブタノール（BuOH）を加えて分配抽出して得
られる水相抽出成分、または、この水相成分中の分子量
５千以上の分画成分を有効成分とすることを特徴とす
る。(Means for Solving the Problems) In order to solve the above problems, the antiallergic agent of the present invention dissolves an extraction component obtained by extracting black tea or oolong tea with water or hot water in water, and then adding methyl -An iso-butyl ketone (MIBK) is added for partition extraction, and an aqueous phase extract component obtained by adding and extracting 1-butanol (BuOH) to an aqueous phase extract component obtained, or a molecular weight in the aqueous phase component is obtained. It is characterized in that 5,000 or more fractionated components are used as active ingredients.
また、本発明の抗アレルギー剤は、上記有効成分を患
部に直接浸透可能な噴霧剤乃至塗布剤としても使用する
ことができる。ただし、このような剤型に限定されるも
のではない。Further, the antiallergic agent of the present invention can also be used as a spray or coating agent capable of directly penetrating the active ingredient into the affected area. However, it is not limited to such a dosage form.
（作用） 例えば、紅茶の熱水抽出成分を水に溶解し、これをメ
チル−イソ−ブチルケトン（MIBE）と１−ブタノール
（BuOH）とを使用し分配抽出して得られる水相抽出成分
を合成吸着剤により分離し、さらに限外濾過により分離
した分子量５千以上の物質の抗アレルギー活性は、現行
市販の抗アレルギー剤であるトラニラストの約250倍で
ある。前述した新規なるタンニンは分子量600〜2000程
である。よって、これらと明らかに異なる物質である。(Action) For example, a hot water extract component of black tea is dissolved in water, and this is partitioned and extracted using methyl-iso-butylketone (MIBE) and 1-butanol (BuOH) to synthesize an aqueous phase extract component. The antiallergic activity of a substance having a molecular weight of 5,000 or more separated by an adsorbent and further separated by ultrafiltration is approximately 250 times that of tranilast, a currently commercially available antiallergic agent. The new tannin described above has a molecular weight of about 600-2000. Therefore, they are clearly different from these.
（実施例） （１）抽出方法 各物質の分画方法を以下に示した。(Examples) (1) Extraction method The fractionation method of each substance is shown below.
紅茶葉200gを３の熱水で抽出した後、濃度、凍結乾
燥し、47.4gの凍結乾燥物（以下FDと記す）を蒸留水に
溶解し、メチル−イソ−ブチルケトン（以下MIBKと記
す）と１−ブタノール（以下BuOHと記す）を用い、分配
抽出を行い、次いでカラムクロマトグラフィーによる分
離、限外濾過による分離を、第１図に示すごとく行っ
た。After extracting 200g of black tea leaves with 3 hot waters, freeze-dry the concentration, 47.4g of the freeze-dried product (hereinafter referred to as FD) is dissolved in distilled water, and methyl-iso-butylketone (hereinafter referred to as MIBK) Partition extraction was performed using 1-butanol (hereinafter referred to as BuOH), and then separation by column chromatography and ultrafiltration were performed as shown in FIG.
即ち、紅茶FD100gを蒸留水４に溶解し、MIBKを加え
分液ロートによる分配抽出を行い、MIBK抽出物20.4gとH
2O抽出物Ｉを76.1g得た。次いでH2O抽出物ＩにBuOHを加
え同様に抽出操作を行い、BuOH抽出物26.3gとH2O抽出物
IIを45.8g得た。その後H2O抽出物IIを合成吸着剤（三菱
化成株式会社製品、商品名ダイヤイオンHP−20を使用）
を用いて溶離液とし、蒸留水とメタノール（MeOH）を通
液し、カラムクロマトグラフィーによる分離を行い、H2
O溶出物35.3gとMeOH溶出物6.7gを得た。That is, 100 g of black tea FD was dissolved in distilled water 4, MIBK was added, and distribution extraction was performed with a separating funnel, and 20.4 g of MIBK extract and H
76.1 g of 2 O extract I was obtained. Next, BuOH was added to the H 2 O extract I and the extraction operation was performed in the same manner, and 26.3 g of the BuOH extract and the H 2 O extract
45.8 g of II was obtained. After that, H 2 O extract II was added to synthetic adsorbent (Mitsubishi Kasei Co., Ltd., product name: Diaion HP-20)
Using as eluent, passed through distilled water and methanol (MeOH), subjected to separation by column chromatography, H 2
35.3 g of O eluate and 6.7 g of MeOH eluate were obtained.
得られたMeOH溶出物を蒸留水に溶解して、0.5％溶液
とし、DIAFLO ULTRAFILTRATION MEMBRANES YM10及び
YM5（グレースジャパン株式会社製）を用い、限外濾過
を行い、分子量１万以上、５千以上１万以下、５千以下
の各々の分画を得た。各分画は、0.67g、0.62g、1.58g
であった。The obtained MeOH eluate was dissolved in distilled water to make a 0.5% solution, and DIAFLO ULTRAFILTRATION MEMBRANES YM10 and
Ultrafiltration was performed using YM5 (manufactured by Grace Japan Co., Ltd.) to obtain each fraction having a molecular weight of 10,000 or more, 5,000 or more, 10,000 or less, and 5,000 or less. Each fraction is 0.67g, 0.62g, 1.58g
Met.
ウーロン茶も同様に、抽出操作を行い、MIBK抽出物、
BuOH抽出物、H2O抽出物、H2O溶出物、MeOH溶出物を得
た。ウーロン茶については、限外濾過を行わなかった。Similarly, the oolong tea is subjected to the extraction operation, and the MIBK extract,
A BuOH extract, a H 2 O extract, an H 2 O eluate, and a MeOH eluate were obtained. For oolong tea, no ultrafiltration was performed.
（２）分析方法 上記の方法で得られた各抽出物、溶出物について以下
のように分析を行った。(2) Analysis method Each extract and eluate obtained by the above method was analyzed as follows.
脱血致死させたWistar系雄性ラットの腹腔内にTyrode
液を注入し、公知の方法により肥満細胞を単離し、106
個/mlとなるようにPBSに懸濁し、細胞浮遊液を調整し
た。各抽出物を各濃度に調整した試料溶液に上記細胞浮
遊液を加えて37℃、10分間放置した後、脱顆粒誘発剤
（シグマケミカルカンパニー製商品名コンパウンド48/8
0を使用）を加え37℃、５分間反応させた。その後氷冷
したPBSを加え反応を停止、遠心分離（1000×ｇ、５分
間）した上清中に遊離されたヒスタミン量を高速液体ク
ロマトグロフィーにより測定した。Intraperitoneal Tyrode of Wistar male rats killed by exsanguination
Liquid is injected, the mast cells were isolated by a known method, 106
The cells were suspended in PBS to give a cell suspension / ml and a cell suspension was prepared. The above cell suspension was added to a sample solution in which each extract was adjusted to each concentration, and the mixture was allowed to stand at 37 ° C. for 10 minutes.
0 was used) and reacted at 37 ° C. for 5 minutes. Thereafter, ice-cooled PBS was added to stop the reaction, and the amount of histamine released in the supernatant subjected to centrifugation (1000 × g, 5 minutes) was measured by high-performance liquid chromatography.
なお、脱顆粒誘発剤の濃度10μg/mlとし、ヒスタミン
遊離抑制活性は、次の式により算出した（単離はいずれ
もpmol）。The concentration of the degranulation-inducing agent was set at 10 μg / ml, and the histamine release inhibitory activity was calculated by the following equation (pmol for isolation).
［１−（Ｓ−Ｃ）／（Ｒ−Ｃ）］×100 C;無処置細胞（試料も刺激剤も加えない細胞） R;刺激剤だけを加えた細胞から遊離されるヒスタミン量 S;試料と刺激剤を加えた細胞から遊離されるヒスタミン
量 上記の方法で各抽出物のヒスタミン遊離抑制活性を分
析した結果を、表１及び表２に、各抽出物の60％ヒスタ
ミン遊離抑制濃度IC60（以下IC60と記す）を表３、表４
に示した。[1- (SC) / (RC)] × 100 C; untreated cells (cells to which neither sample nor stimulant was added) R; amount of histamine released from cells to which only stimulant was added S; sample And the amount of histamine released from the cells to which the stimulant was added. The results of analyzing the histamine release inhibitory activity of each extract by the above method are shown in Tables 1 and 2, and the 60% histamine release inhibitory concentration IC 60 of each extract is shown in Tables 1 and 2. Table 3 and Table 4 (hereinafter referred to as IC 60 )
It was shown to.
（３）結果 表1,2に示したように、紅茶、ウーロン茶のの各抽出
物は高いヒスタミン遊離抑制作用があることが確認され
た。 (3) Results As shown in Tables 1 and 2, it was confirmed that each extract of black tea and oolong tea had a high histamine release inhibitory action.
表3,4に示したIC60で公知の抗アレルギー剤であるト
ラニラストと比較してみた。It was compared with Tranilast, a known anti-allergic agent, with an IC 60 shown in Tables 3 and 4.
公知の抗アレルギー剤であるトラニラストは、同じ試
験系では、1.0mg/mlで約60％のヒスタミン遊離抑制作用
を持つ。即ちIC60は1.0mg/mlである。本発明で得られた
各抽出物は、はるかに高いヒスタミン遊離抑制作用を持
つ。例えば、紅茶のFDのIC60は0.15mg/mlでありトラニ
ラストの６倍以上、同様にH2O抽出物IIは約20倍、MeOH
溶出物は約100倍、限外濾過で得られた各物質は約250倍
以上、ウーロン茶のFDは約９倍、MeOH溶出物は約50倍の
ヒスタミン遊離抑制作用を持つという結果が得られた。
従って本発明で得られた各抽出物は、トラニラストより
低い濃度で従来以上の効果が奏せられることが判明し
た。Tranilast, a known antiallergic agent, has a histamine release inhibitory effect of about 60% at 1.0 mg / ml in the same test system. That is, IC 60 is 1.0 mg / ml. Each extract obtained in the present invention has a much higher histamine release inhibitory action. For example, the FD of black tea has an IC 60 of 0.15 mg / ml, which is more than 6 times that of tranilast. Similarly, H 2 O extract II is about 20 times
The eluate was about 100 times, each substance obtained by ultrafiltration was about 250 times or more, FD of oolong tea was about 9 times, and MeOH eluate was about 50 times that of histamine release. .
Therefore, it was found that each extract obtained in the present invention can exert more effects than the conventional one at a concentration lower than that of tranilast.
（発明の効果） 本発明によれば、入手容易な茶乃至茶葉を原料とし、
既に確立された簡便な抽出技術を利用して製造容易な紅
茶、ウーロン茶の抽出物、溶出物を用いることによっ
て、例えば公知の抗アレルギー剤であるトラニラストの
約250倍等の如き高い効果を奏する抗アレルギー剤を提
供することが可能となる。この成分は自然食物から得ら
れ、日常常用しているものであるので、合成物等に比し
て安全性が高いとい利点も有している。(Effects of the Invention) According to the present invention, easily available tea or tea leaves are used as raw materials,
By using an easily-produced black tea, oolong tea extract, and eluate using a simple and well-established extraction technique, an anti-allergic agent, such as tranilast, which is a known anti-allergic agent, has an effect as high as about 250 times. It becomes possible to provide an allergic agent. Since this component is obtained from natural foods and is commonly used on a daily basis, it also has an advantage that its safety is higher than that of synthetic products.
この抗アレルギー剤は直接患部に噴霧乃至塗布して皮
膚吸収させることによって一層顕著な効用を発揮させる
ことができる。The antiallergic agent can exert more remarkable effects by directly spraying or applying it to the affected area and absorbing it to the skin.
図面は本発明に係る抗アレルギー剤を得るための抽出方
法の一例を示すフロチャートである。The drawing is a flowchart showing an example of an extraction method for obtaining the antiallergic agent according to the present invention.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 横田 正實 静岡県静岡市瀬名200―16 大学公舎104 (56)参考文献 特開 昭59−196884（ＪＰ，Ａ) 特開 平１−128933（ＪＰ，Ａ) 特開 平２−11520（ＪＰ，Ａ) (58)調査した分野(Int.Cl.6，ＤＢ名) A61K 35/78 ──────────────────────────────────────────────────続 き Continuation of the front page (72) Inventor Masami Yokota 200-16 Sena, Shizuoka City, Shizuoka Prefecture 104 (56) References JP-A-59-196884 (JP, A) JP-A-1-128933 (JP, A) JP-A-2-11520 (JP, A) (58) Fields investigated (Int. Cl. 6 , DB name) A61K 35/78
Claims (2)
て得られる抽出成分を水に溶解し、これにメチル−イソ
−ブチルケトン（MIBK）を加えて分配抽出し、得られる
水相抽出成分に１−ブタノール（BuOH）を加えて分配抽
出して得られる水相抽出成分を有効成分とする抗アレル
ギー剤。An aqueous phase extract obtained by dissolving an extract obtained by extracting black tea or oolong tea with water or hot water, adding methyl-iso-butylketone (MIBK) to the extract and distributing and extracting the extract. An antiallergic agent comprising, as an active ingredient, an aqueous phase extract obtained by partitioning and adding 1-butanol (BuOH) to a mixture.
相抽出成分中の分子量５千以上の分画成分を有効成分と
する請求項１に記載の抗アレルギー剤。2. The antiallergic agent according to claim 1, wherein a fraction component having a molecular weight of 5,000 or more in the aqueous phase extract obtained by the 1-butanol partition extraction is used as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2057392A JP2920151B2 (en) | 1990-03-08 | 1990-03-08 | Antiallergic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2057392A JP2920151B2 (en) | 1990-03-08 | 1990-03-08 | Antiallergic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03258726A JPH03258726A (en) | 1991-11-19 |
| JP2920151B2 true JP2920151B2 (en) | 1999-07-19 |
Family
ID=13054346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2057392A Expired - Lifetime JP2920151B2 (en) | 1990-03-08 | 1990-03-08 | Antiallergic agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2920151B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10175874A (en) * | 1996-12-19 | 1998-06-30 | Suntory Ltd | Antiallergic agent |
| US6991812B2 (en) | 2000-09-05 | 2006-01-31 | Kao Corporation | Agent for preventing, improving or treating hypertension |
| JP5096750B2 (en) * | 2007-01-22 | 2012-12-12 | 株式会社ナリス化粧品 | Allergen inactivating agent and skin external preparation containing the same, or allergen inactivating product |
| JP5891004B2 (en) * | 2011-10-31 | 2016-03-22 | マイクロアルジェコーポレーション株式会社 | Carcinogenesis promotion inhibitor and method for producing the same |
-
1990
- 1990-03-08 JP JP2057392A patent/JP2920151B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03258726A (en) | 1991-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5615966B2 (en) | Piceatannol-containing composition | |
| JP6196346B2 (en) | Use of lignan compounds to improve wrinkles | |
| AU2016245203B2 (en) | An extract from indigo naturalis and a process for preparing the same | |
| JP2006515290A (en) | Witania somnifera composition, method for obtaining it, and pharmaceutical formulations, nutritional agents and personal care formulations thereof | |
| EP0810222B1 (en) | Process for extraction of polyphenolic compounds of catechin type from plants, the so obtained extract and its use | |
| KR20170053388A (en) | Cosmetic composition comprising mixture extracts of curcuma longa Linn, apple, grape, having anti-pollution effect in skin cells and method manufacturing thereof | |
| WO2011080721A2 (en) | A herbal composition as hepatoprotective and treatment for liver disorders | |
| CN114907202A (en) | Preparation and application of pepper active extract, pepper polyphenol and composition thereof | |
| KR20030021640A (en) | Extracts of Phyllostachys edulis leaf having antioxidant activity and the process for preparation thereof | |
| JP2920151B2 (en) | Antiallergic agent | |
| KR101253433B1 (en) | Method for preparing tea water and tea water prepared by same method | |
| JP5436823B2 (en) | MIF secretion inhibitor | |
| KR102221627B1 (en) | Composition comprising Rhus Semialata extract as active ingredient | |
| CA2087600C (en) | Antineoplastic chemotherapeutic of plant origin, having high selectivity and greatly reduced toxicity, and process for the preparation thereof | |
| KR20140000757A (en) | Novel sulfated phenolic compounds isolated from the leaves of myrica rubra sieb. et zucc and anti-oxidative and anti-inflammatory use thereof | |
| KR20180005520A (en) | Method for Producing Ginseng Stem and Leaf Extract | |
| CN115209871A (en) | Cosmetic composition for enhancing skin beneficial bacteria | |
| JP4071466B2 (en) | Novel orcinol derivatives | |
| JPH0398562A (en) | Beverage composition | |
| AU2014330796B2 (en) | Extracts and compositions of Helichrysum odoratissimum for preventing and treating skin cancers | |
| KR100835093B1 (en) | Anti-allergy skin care cosmetic composition | |
| JP3182047B2 (en) | Cosmetic composition containing an ingredient extracted from brown sugar | |
| JP2884166B2 (en) | Anti-dermatophyte | |
| KR101977051B1 (en) | Cosmetics Composition Containing Compounds Having Anti-oxidant, Anti-inflammatory and Anti-wrinkle Derived from Hwangsook-jong | |
| JPS63264529A (en) | Production of antiphlogistics from phellodendri cortex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100430 Year of fee payment: 11 |
|
| EXPY | Cancellation because of completion of term |